New Immunooncology Drug from Incyte Raises Immense Interest at ASCO

We just got our first look at the clinical activity of

(INCY)

immuno-oncology candidate INCB024360 ('360) dosed at 50 mg and combined with

(BMY)

Yervoy in melanoma patients

Incyte'sBristol-Myers Squibb's

Four immunotherapy-naive melanoma patients dosed with 50 mg of '360 plus Yervoy yielded 1 complete response and 1 partial response for an overall response

of 50%. A third patient reported stable disease so the disease control rate was 75%. The

.

Story:

rateIncyte press release and poster can be found herehttp://bit.ly/1pP7ZeT

Source: The Street